<DOC>
	<DOCNO>NCT02726009</DOCNO>
	<brief_summary>The purpose open-label , single-arm , multicenter , post-marketing trial evaluate long-term safety Firmagon® approximately 230 Indian patient diagnose advanced hormone-dependent prostate cancer require androgen deprivation therapy .</brief_summary>
	<brief_title>A Trial Evaluate Safety Firmagon® ( Degarelix ) Indian Patients Diagnosed With Advanced Hormone-dependent Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Has give write informed consent studyrelated activity perform Advanced hormonedependent prostate cancer androgen deprivation therapy indicate Age great equal 18 year less 80 year Advanced hormonedependent prostate cancer without clinically significant disorder PSA ≥ 2 ng/mL screen Previous concurrent hormonal management prostate cancer Contraindication prescription Firmagon® Concurrent treatment 5αreductase inhibitor Considered candidate curative therapy History severe untreated asthma , anaphylactic reaction severe urticaria and/or angioedema QTc interval 450 msec risk factor torsades de pointes Class IA Class III anti arrhythmic medication Cancer within last 5 year except prostate cancer surgically remove basal squamous cell carcinoma skin Known suspect hepatic , symptomatic biliary disease ( include moderate severe chronic hepatic impairment ) Patients urinary catheterization / clinically significant laboratory abnormality / disorder prostate cancer Patient Hepatitis B Virus ( HBV ) , Hepatitis C Virus ( HCV ) Human Immunodeficiency Virus ( HIV ) infection</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>